Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | 300-313 |
| Numero di pagine | 14 |
| Rivista | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
| Volume | 89 |
| Stato di pubblicazione | Published - 2013 |
Fingerprint
Cita questo
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. / Fiorentino, Eugenio; Russo, Antonio; Cicero, Giuseppe; Rizzo, Sergio; Bronte, Giuseppe; Castiglia, Marta; Passiglia, Francesco; Rolfo, C; Giovannetti, E; Pauwels, P; Vullo, Fl; Van Meerbeeck, J.
In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, Vol. 89, 2013, pag. 300-313.Risultato della ricerca: Article
}
TY - JOUR
T1 - Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
AU - Fiorentino, Eugenio
AU - Russo, Antonio
AU - Cicero, Giuseppe
AU - Rizzo, Sergio
AU - Bronte, Giuseppe
AU - Castiglia, Marta
AU - Passiglia, Francesco
AU - Rolfo, C; Giovannetti, E; Pauwels, P; Vullo, Fl; Van Meerbeeck, J
PY - 2013
Y1 - 2013
N2 - Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of 'oncogene addiction', with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients.
AB - Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of 'oncogene addiction', with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacokinetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients.
UR - http://hdl.handle.net/10447/104198
M3 - Article
VL - 89
SP - 300
EP - 313
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -